Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical (89)Zr-immuno-PET

PURPOSE: Almost all radiolabellings of antibodies with (89)Zr currently employ the hexadentate chelator desferrioxamine (DFO). However, DFO can lead to unwanted uptake of (89)Zr in bones due to instability of the resulting metal complex. DFO*-NCS and the squaramide ester of DFO, DFOSq, are novel ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Chomet, Marion, Schreurs, Maxime, Bolijn, Maria J., Verlaan, Mariska, Beaino, Wissam, Brown, Kari, Poot, Alex J., Windhorst, Albert D., Gill, Herman, Marik, Jan, Williams, Simon, Cowell, Joseph, Gasser, Gilles, Mindt, Thomas L., van Dongen, Guus A. M. S, Vugts, Danielle J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036225/
https://www.ncbi.nlm.nih.gov/pubmed/32889615
http://dx.doi.org/10.1007/s00259-020-05002-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036225/
https://www.ncbi.nlm.nih.gov/pubmed/32889615
http://dx.doi.org/10.1007/s00259-020-05002-7

Ejemplares similares